---
schema_version: "secwatch.filing_event.v1"
accession: "0000899923-25-000002"
form_type: "8-K"
ticker: "MYGN"
cik: "0000899923"
company_name: "MYRIAD GENETICS INC"
filed_at: "2025-01-15T23:59:59+00:00"
generated_at: "2026-05-28T01:37:03.260070+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Myriad Genetics reports preliminary Q4 rev $209-211M, FY2025 adj EPS guidance $0.07-0.11

## Summary
- Q4 2024 preliminary revenue $209-211M (+6-7% YoY); GAAP diluted loss $(0.72)-(0.62)/share; adj EPS $0.03-$0.04.
- Full year 2024 preliminary revenue $836-838M (+11% YoY); GAAP loss $(1.66)-(1.56)/share; adj EPS $0.14-$0.15.
- Cash and equivalents $102M as of Dec 31, 2024, up $2M from Q3.
- FY2025 guidance: revenue $840-860M (0-3% growth); adj EPS $0.07-$0.11; adj EBITDA $25-35M.
- FY2025 guidance reflects impact from UnitedHealthcare coverage changes and EndoPredict divestiture.

## SEC filing metadata
- accession: 0000899923-25-000002
- form_type: 8-K
- ticker: MYGN
- cik: 0000899923
- company_name: MYRIAD GENETICS INC
- filed_at: 2025-01-15T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/899923/000089992325000002/0000899923-25-000002-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/899923/000089992325000002/mygn-20250115.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000899923-25-000002
- JSON: https://secwatch.observer/filing/0000899923-25-000002.json
- Plain text: https://secwatch.observer/filing/0000899923-25-000002.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.